IP Library Granted Patent US 7,250,429
Granted Patent B2
US 7,250,429 · App. 10/508,329 · Granted Jul 31, 2007

Aminomethyl-substituted thiazolobenzimidazole compounds

Assignee: Astellas Pharma Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,250,429
App. No.
10/508,329
Granted
Jul 31, 2007
Kind
B2
Abstract

This invention relates to the provision of novel aminomethyl-substituted thiazolobenzimidazole derivatives represented by the following general formula (I) or a salt thereof. The aforementioned derivative or a salt thereof has a metabotropic glutamate receptor action and excellent oral activity and is therefore useful as a medicament. (In the formula, R 1 : an oxygen-containing saturated hetero ring or the like, Alk 1 : a lower alkylene, m: 0 or 1, Alk 2 : a lower alkylene which may be substituted with oxo group, n: 0 or 1, X: a bond, O, S or NR 5 , R 3 : H or the like, and R 2 , R 4 , R 5 , R 6 and R 7 : the same or different from one another and each represents H or the like. Provided that R 3 does not represent a lower alkyl or a halogeno-lower alkyl when X is a bond and n is 1. Also, R 4 represents a group other than Me when m is 1, R 1 is OH or OMe and Alk 1 is a C 1-3 alkylene, and further 1) when X is a bond, n is 1 and R 3 is H, or 2) when X is a bond, n is 0 and R 3 is cyclohexane.)

Claims (12)

1. An aminomethyl-substituted thiazolobenzimidazole compound represented by the following formula (I) or a salt thereof

(wherein signs in the formula mean as follows;

R 1 : an oxygen-containing saturated hetero ring- which may be substituted,

Alk1: a lower alkylene,

m: 0 or 1,

Alk2: a lower alkylene which may be substituted with oxo group,

n: 0 or 1,

X: a bond, O, S or NR 5 ,

R 3 : a lower alkyl or a saturated hetero ring-, and

R 2 , R 4 and R 5 : the same or different from one another and each represents H or lower alkyl, with the proviso that R 3 does not represent a lower alkyl when X is a bond and n is 1).

2. A compound selected from the group consisting of N-methyl-N-neopentyl-6-[(oxetan-3-ylamino)methyl]thiazolo[3,2-a]benzimidazole-2-carboxamide; 6-{[(1,3-dioxolan-2-ylmethyl)amino]methyl}-N-methyl-N-neopentylthiazolo[3,2-a]benzimidazole-2-carboxamide; and N-neopentyl-6-({[tetrahydro-2H-pyran-4-yl)methyl]amino}methyl)thiazolo[3,2-a]benzimidazole-2-carboxamide; or a salt thereof.

3. A medicament which comprises the aminomethyl-substituted thiazolobenzimidazole compound described in claim 1 or a salt thereof as the active ingredient.

Assignments (2)
MERGER Recorded Sep 22, 2005
From: YAMANOUCHI PHARMACEUTICAL CO., LTD.
To: ASTELLAS PHARMA INC.
Reel/Frame 016570/0324 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 20, 2004
From: ITAHANA, HIROTSUNE; FUJIYASU, JIRO; HAYASHIBE, SATOSHI; WATANABE, TOSHIHIRO; OKADA, MASAMICHI; TOYA, TAKASHI
To: YAMANOUCHI PHARMACEUTICAL CO., LTD.
Reel/Frame 016383/0073 →
Priority Claims (1)
JP 2002-077431 · Mar 20, 2002 · national
Continuity (1)
Related Publication 20050148642A1 · Jul 7, 2005